EMD Serono Media Center
Latest NewsView all news
Merck KGaA, Darmstadt, Germany, announced a research collaboration and commercial license agreement with Mersana Therapeutics, Inc., Cambridge, Massachusetts, USA
Merck KGaA today shared updates on the company’s healthcare research and development strategy, aimed at doubling R&D productivity.
This data suggests the long-term positive benefits of evobrutinib for people with RMS as a potential best-in-class therapy.
The Media Center is a service for journalists, bloggers and online multipliers that allows you to access news about EMD Serono.